Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474

Cancer Research

Volumn 64, Issue 24, 2004, Pages 9101-9104

  Arao, Tokuzo ^a   Fukumoto, Hisao ^a   Takeda, Masayuki ^a   Tamura, Tomohide ^a   Saijo, Nagahiro ^a   Nishio, Kazuto ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATP BINDING SITE; BINDING SITE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN PC 9; CONTROLLED STUDY; DELETION MUTANT; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; GENE DELETION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN FRAME DELETION; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR MODEL;

BASE SEQUENCE; CELL LINE, TUMOR; GENE DELETION; GENES, ERBB-1; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PIPERIDINES; QUINAZOLINES; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 10844268011     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2360     Document Type: Article

References (15)

1. Ciardiello F, Caputo R, Tortora G, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
2. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
3. Koizumi F, Kanzawa F, Nishio K, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004;108:464-72.
4. Lynch TJ, Bell DW, Haber DA, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
5. Paez JG, Janne PA, Meyerson M, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
6. Ohm JE, Amann JM, Carbone DP. Acquired EGFr TKI resistance associated with mutation of the EGFr. Presented at the 95th Annual Meeting of the American Association of Cancer Research, November 17-21, 2004, Bonita Springs, FL.
7. Ciardiello F, Caputo R, Tortora G, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
8. Naruse I, Ohmori T, Nishio K, et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002;98:310-5.
9. Koizumi F, Taguchi F, Shimoyama T, Saijo N, Nishio K. Mechanism of resistance to epidermal growth factor receptor inhibitor ZD1839: a role for inhibiting phosphorylation of EGFR at Tyr1068. Presented at the 94th Annual Meeting of the American Association of Cancer Research, July 11-14, 2003, Washington, DC.
10. Kawamura-Akiyama Y, Kusaba H, Nishio K, et al. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines. Lung Cancer 2002;38:43-50.
11. Nishio K, Arioka H, Saijo N, et al. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Int J Cancer 1995;63:688-93.
12. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci USA 2003;100:9330-5.
13. Ciardiello F, Bianco R, Tortora G, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784-93.
14. Taguchi F, Koh Y, Nishio K, et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (Iressa) sensitive and resistant xenograft models. Cancer Sci 2004;in press.
15. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.